anpc - ANPC STOCK NEWS

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has completed a registered direct offering, raising approximately $3.0 million from institutional investors. This offering involved the sale of 625,000 American Depositary Shares (ADSs) at $4.00 per ADS, along with pre-funded warrants and additional warrants. Proceeds will be utilized for research and development, working capital, and general corporate purposes. The company aims to expand into the business-to-business e-commerce food sector through a new subsidiary, Fresh2 Technology Inc. AnPac currently holds 155 patents and operates certified laboratories in both the U.S. and China for cancer screening and detection.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced on April 3, 2023, that it has entered into an asset purchase agreement with Easy Hundred Inc. for $8,149,595. This acquisition includes the intellectual property and fixed assets related to Easy Hundred's e-commerce platforms: ez100, 2Supply, and 100WAY. The transaction, finalized on March 31, 2023, aims to enhance AnPac's entry into the U.S. food market, aligning with its strategy to optimize the supply chain and complement its existing operations with Fresh2 Ecommerce Inc. The acquisition is expected to bolster the company’s growth prospects in the competitive food service sector.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced a registered direct offering to institutional investors, raising approximately $3.0 million by selling 625,000 American Depositary Shares (ADSs) at $4.00 each. The offering will also include pre-funded and warrants for purchasing additional ADSs. Net proceeds will be allocated to advance research and development, working capital, and general corporate purposes. The offering is expected to close on or around April 5, 2023. A lock-up period of 120 days on further securities issuance will be in effect for the Company.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) has been granted continued listing on Nasdaq's Capital Market, contingent on meeting the shareholder equity requirement by July 12, 2023. The Nasdaq Hearings Panel acknowledged the company's efforts to address its previous equity deficiency and plans for ongoing fundraising. The company aims to enhance its financial position through cost-reduction strategies and the acquisition of a food e-commerce business, Fresh2 Technology Inc. AnPac's operations focus on early cancer detection and screening, supported by its patented technologies and accredited laboratories.

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) announced it received a $1.5 million payment from a Malaysian customer for its Model AP9080 cancer detection devices, marking its entry into the Southeast Asia market. This sale represents a significant milestone, confirming the Company's Cancer Differentiation Analysis Technology (CDA). The contract includes maintenance services and consumables, providing ongoing revenue. With a strong reputation in multi-cancer testing, AnPac Bio aims to capitalize on growth opportunities in Asia, driven by its patented technology known for high sensitivity and cost-effectiveness.

AnPac Bio-Medical Science Co., Ltd. (Nasdaq: ANPC) announced a definitive agreement for a private placement raising US$5 million by issuing 16,666,665 shares at US$0.30 each. This transaction, expected to close by the end of March 2023, aims to support working capital and the expansion of a new business-to-business e-commerce platform for Asian food products in the US. The shares sold are not registered under the Securities Act and are part of an offshore transaction under Regulation S. AnPac Bio specializes in cancer detection and screening, holding 155 patents as of June 30, 2022.